hotspot -WSS

hotspot

author：hotspot 2025-10-02 01:07:26 - browse：667

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Boston's new lab space is opening empty

entertainment

WSS

Boston's new lab space is opening empty

John Green on his newest strategy for fighting tuberculosis

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

First U.S. drug developed to treat liver disease MASH is approved

EQRx, failed developer of low

Steward Health Care Massachusetts hospitals face fiscal disaster

explore

hotspot

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

As AI in medicine takes off, can 'human in the loop' prevent harm?

Trump demands the U.S. pay no more for drugs than other countries … again

President Biden's budget: Here's what you might have missed

Medicare details structure of new drug price negotiation program

Pushing for an NIH office for post

Novavax promises a turnaround & Lilly roils the obesity market

Ebola: Gilead Sciences antiviral shows promise as new treatment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

National panel will explore requiring free Covid tests

hotspot

Amid AI frenzy, a top HHS official's quest to create safeguards

Micronoma's microbiome cancer diagnostic approach under fire

5 important ways Henrietta Lacks changed medical science

Adults seen as increasingly susceptible to measles

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Breakthrough Alzheimer’s drugs are inaccessible in rural states

explore

focus

entertainment

entertainment